Histosonics Delighted to Share Hope4Liver Pivotal Trial Results
Histotripsy, a groundbreaking non-invasive therapy, has gained significant momentum following its FDA clearance. Pivotal clinical trials revealed its exceptional...
Jon Napitupulu
AngioDynamics Auryon System Now Available in Europe
AngioDynamics has secured CE Mark approval for its innovative Auryon Atherectomy System, a groundbreaking technology for treating Peripheral Artery...
MedinCell Unveils Remarkable Progress in Product and R&D Pipeline with Abbvie
Medincell has partnered with AbbVie to develop and commercialize up to six innovative therapies using Medincell’s long-acting injectable platform....
Merck Keytruda and Padcev Advance Urothelial Carcinoma Treatment: An Uncommon Breakthrough
The European Commission (EC) has granted approval to the combination of KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin) as a...
Pyros Pharma’s Vigafyde: The Breakthrough Oral Solution for Infantile Spasm
Pyros Pharmaceuticals introduces VIGAFYDE™, an oral solution containing vigabatrin for treating infantile spasms (IS) in children aged 1 month...
Aixial Group’s Clinical Data Migration: Unlocking Efficiency and Breakthroughs
Medidata, a renowned provider of clinical trial solutions, has partnered with Aixial Group, a contract research organization (CRO), to...
Unveiling Healthcare Gaps and Unmet Needs: Daiichi Sankyo’s Devotion to Heart Health
Daiichi Sankyo is committed to addressing neglected needs in cardiovascular care, highlighting disparities in treatment and outcomes between different...
Median’s Revolutionary Lung Cancer Diagnostic Earns Pivotal Validation
Median Technologies’ eyonis™ LCS, an AI-powered SaMD for lung cancer screening, has demonstrated strong performance in its REALITY pivotal...
Merck Discontinues Two Phase 3 Trials
Merck has discontinued two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. The KEYNOTE-867 trial evaluated the combination of KEYTRUDA (pembrolizumab)...
ESC Congress 2024: Bayer Presents Phase III Kerendia® (Finerenone) Data
During the 2024 European Society of Cardiology (ESC) Congress, Bayer will unveil late-breaking results from the Phase III FINEARTS-HF...